Hansoh Pharmaceutical Group (HKG:3692) said an additional indication of Ameile was granted registration approval by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The additional indication is for use of the drug in combination with pemetrexed and platinum-
based chemotherapy to treat adult patients with locally advanced or metastatic non-small cell lung cancer.
This is the fifth indication of the drug which has been approved.